Ticker Details
Alkermes plc Ordinary Shares Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date:	August 1, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.96B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.52 | 1.99%
Avg Daily Range (30 D):	$1.10 | 2.38%
Avg Daily Range (90 D):	$0.85 | 2.29%

Institutional Daily Volume
Avg Daily Volume:	1.1M
Avg Daily Volume (30 D):	1.79M
Avg Daily Volume (90 D):	1.85M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	65
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	14,600
Avg Institutional Trade:	$2.64M
Avg Institutional Trade (30 D):	$5.28M
Avg Institutional Trade (90 D):	$4.51M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.68M
Avg Closing Trade (30 D):	$29.1M
Avg Closing Trade (90 D):	$17.95M
Avg Closing Volume:	188.35K

News

Jun 8, 2026 @ 5:00 PM Alcohol Use Disorder Market Set to Expand at a 12.... Source: Delveinsight

Feb 23, 2026 @ 3:26 PM Viridian Therapeutics Stock Up 75%, but One Fund J... Source: Jonathan Ponciano

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Feb 10, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces Outcome of the Co... Source: Globe Newswire

Jan 12, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces that Avadel Share... Source: Globe Newswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.93	$-.4	$.3
Diluted EPS	$.9	$-.4	$.29
Revenue	$1.56B	$392.91M	$384.55M
Gross Profit	$1.35B	$331.33M	$338.34M
Net Income / Loss	$152.72M	$-66.48M	$49.34M
Operating Income / Loss	$191.88M	$-48.28M	$58.1M
Cost of Revenue	$208.84M	$61.58M	$46.21M
Net Cash Flow	$-48.25M	$-768.22M	$503.33M
PE Ratio

Splits
May 15, 2000	2:1